Literature DB >> 12220518

Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer.

Nicolai Maass1, Marco Biallek, Frank Rösel, Christian Schem, Nobuyuki Ohike, Ming Zhang, Walter Jonat, Koichi Nagasaki.   

Abstract

Maspin is a member of the serine protease inhibitor family with tumor suppressing activity in breast cancer. Maspin expression was found in normal breast epithelial cells, but was frequently decreased in breast cancer cells and lost in metastatic cells. In this study, we examined the regulatory mechanism of maspin expression and described the re-activation of maspin expression in a series of maspin-negative breast cancer cell lines. All of the 6 maspin-negative breast cancer cells showed induction of maspin promoter activity in a promoter reporter assay. In addition, the treatment of 5-aza-2(') deoxycytidine, trichostatin A or a combination of both led to the re-expression of maspin in a series of maspin-negative breast cancer cell lines. These findings indicate that DNA methylation and/or histone deacetylation are/is partially responsible for the silencing of maspin gene expression in breast cancer cells. The re-expression of maspin by pharmacological intervention potentially offers a promising new target as a therapeutic option in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220518     DOI: 10.1016/s0006-291x(02)02136-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

Review 1.  Flipping the epigenetic switch.

Authors:  Frederick E Domann; Bernard W Futscher
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

2.  Aberrant methylation of the maspin promoter is an early event in human breast cancer.

Authors:  Bernard W Futscher; Megan M O'Meara; Christina J Kim; Margaret A Rennels; Di Lu; Lynn M Gruman; Richard E B Seftor; Mary J C Hendrix; Frederick E Domann
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 3.  A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.

Authors:  A R Lourenço; P J Coffer
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 4.  Maspin: the new frontier.

Authors:  Zhila Khalkhali-Ellis
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

5.  Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics.

Authors:  Mohsen Karimi Arzenani; Atosa Esteki Zade; Yu Ming; Susanne J H Vijverberg; Zhe Zhang; Zahidul Khan; Syed Sadique; Lorenz Kallenbach; LiFu Hu; Vladana Vukojević; Tomas J Ekström
Journal:  Mol Cell Biol       Date:  2011-07-26       Impact factor: 4.272

6.  Epigenetic Therapy in Breast Cancer.

Authors:  Maryam B Lustberg; Bhuvaneswari Ramaswamy
Journal:  Curr Breast Cancer Rep       Date:  2011-03

7.  Maspin expression in gastrointestinal stromal tumors.

Authors:  Saduman Balaban Adim; Gulaydan Filiz; Ozkan Kanat; Omer Yerci; Halil Ozguc; Berna Aytac
Journal:  World J Surg Oncol       Date:  2010-03-26       Impact factor: 2.754

8.  Comparative proteomic analysis of the function and network mechanisms of MASPIN in human lung cells.

Authors:  Yao Liu; Yi Geng; Kuanzhi Li; Fang Wang; Haiping Zhou; Wanhu Wang; Jie Hou; Wenchao Liu
Journal:  Exp Ther Med       Date:  2011-12-22       Impact factor: 2.447

9.  Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control.

Authors:  Matthew Fitzgerald; Marc Oshiro; Nicholas Holtan; Kimberly Krager; Joseph J Cullen; Bernard W Futscher; Frederick E Domann
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

10.  Maspin expression and its clinicopathological significance in tumorigenesis and progression of gastric cancer.

Authors:  Meng-Chun Wang; Yan-Min Yang; Xiao-Han Li; Fang Dong; Yan Li
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.